Changes in heart size during long-term timolol treatment after myocardial infarction. 1984

T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen

The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115). The follow-up period was 12 months. The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group. These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume. The timolol-related increase in heart size was observed only in patients with normal and borderline heart size. In patients with cardiomegaly, the increase in heart size was similar in both groups. After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010138 Pacemaker, Artificial A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external). Cardiac Pacemaker, Artificial,Artificial Cardiac Pacemaker,Artificial Cardiac Pacemakers,Artificial Pacemaker,Artificial Pacemakers,Cardiac Pacemakers, Artificial,Pacemaker, Artificial Cardiac,Pacemakers, Artificial,Pacemakers, Artificial Cardiac
D004071 Digitalis Glycosides Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis. Glycosides, Digitalis
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart

Related Publications

T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
May 1981, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
August 1981, The New England journal of medicine,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
August 1981, British medical journal (Clinical research ed.),
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
January 1983, Diabetes care,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
May 1970, British medical journal,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
April 1970, British medical journal,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
February 1970, British medical journal,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
April 1990, BMJ (Clinical research ed.),
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
August 1983, British heart journal,
T Gundersen, and K Traetteberg, and P Rønnevik, and C von Brandis, and S Barstad, and A M Abrahamsen
January 1987, Advances in experimental medicine and biology,
Copied contents to your clipboard!